Here's what Houston startups won prizes at the inaugural Venture Houston conference. Photo via Getty Images

Just a few months ago, Venture Houston 2021 was just an idea. Now, the two-day conference concluded with over 2,500 registrants and doled out nearly $1 million in cash and investment prizes to startups.

The idea was to bring together startups, investors, corporations, and anyone who cares to advance the Houston tech ecosystem, says Sandy Guitar, managing director at HX Venture Fund, at the closing event. The conference, which was put on by HXVF, the Houston Angel Network, the Rice Alliance, and Houston Exponential, wrapped up with the announcement of nine startups taking home investment or cash prizes.

In its first year, the Venture Houston conference attracted over 266 startup applications, and a group of Houston innovation leaders named 30 semifinalists that pitched on Thursday, February 4. On Friday, February 5, seven finalists pitched:

  • Koda Health
  • Spark Biomedical Inc
  • PATH EX, Inc.
  • Conversifi
  • CellChorus
  • MacroFab, Inc.
  • Mainline

The top three startups in the competition took home cash prizes — Macrofab won first place and $15,000 from Halliburton Labs, Spark Biomedical won second place and $10,000 from Softeq, and PathEx won third place and $5,000 from ChampionX.

  • Work & Mother won $250,000 from The Artemis Fund
  • MacroFab won $250,000 — $100,000 from Mercury Fund and $150,000 from Carnrite Ventures
  • Conversifi won $200,000 — $100,000 from Next Coast Ventures and $100,000 from Live Oak Venture Partners
  • Koda Health won $50,000 from Houston Angel Network
  • CellChorus won $50,000 from Texas Halo Fund
  • Nesh won $50,000 from Plug and Play
  • Cemvita Factory won $25,000 from baMa

Two previously announced prizes — $500,000 from Fitz Gate Ventures and $250,000 from Montrose Lane — were not given out.

The Venture Houston organizers are already looking forward to next year's program, but in the meantime Guitar had a parting call to action.

"Keep helping your fellow entrepreneur," she says, "that's really what Venture Houston 2021 is really about at the end of the day. The entrepreneur journey is a difficult one — often a lonely one — and sometimes one of hard knocks. Please keep finding entrepreneurs within your ecosystem. Let's help them with our advice, our capital, and our understanding."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.